Sign in Subscribe
Legislators

Former Trump Health Official Calls for Paradigm Shift in Chronic Care, Emphasizing Innovative "Upstream" Approaches

Strategic Insights

— 2 min read

Brett P. Giroir, M.D., former Assistant Secretary of Health and Acting FDA Commissioner, has praised the formation of the bipartisan BIOTech Caucus and advocated for a shift in the treatment of chronic conditions, such as Chronic Obstructive Pulmonary Disease (COPD). Giroir, CEO of Altesa BioSciences, highlighted the need for innovative approaches that disrupt the current paradigm of costly chronic care. He pointed to the example of COPD, a condition that affects 17 million Americans and nearly 500 million globally, and costs the U.S. approximately $50 billion annually in healthcare spending.

Key Takeaways:

  • Brett P. Giroir, M.D., former Trump Health Official, urges focus on innovative "upstream" approaches to disrupt costly chronic care paradigms.
  • The formation of the bipartisan BIOTech Caucus is praised for engaging sector leaders and building awareness and bioliteracy among Members of Congress.
  • Chronic Obstructive Pulmonary Disease (COPD) is cited as an example of a condition that requires a transformation in treatment, with 17 million Americans and nearly 500 million affected globally, and costs the U.S. approximately $50 billion annually.
  • Giroir advocates for empowering patients to better care for their disease by using wearable technologies, at-home diagnostics, artificial intelligence, and specific treatments for the number one cause of exacerbations – respiratory virus infections.
  • Altesa BioSciences collaborator, Sensifai Health, is highlighted as an example of the emphasis on AI and upstream treatments to help people experiencing COPD.
  • A peer-reviewed study published in The Lancet Digital Health details Sensifai's AI platform predicting acute inflammation with 90% sensitivity using wearable-powered system.
  • Giroir urges payers like Medicare and Medicaid to evaluate innovative care models that compare costly chronic downstream therapies to upstream approaches like AI-assisted wearables, vaccination, and Vitamin D supplementation.
  • The potential impact of these approaches is significant, with tens of billions of dollars in annual healthcare savings and improved quality of life for patients.

Statistics:

  • COPD affects 17 million Americans and nearly 500 million globally.
  • COPD costs the U.S. approximately $50 billion annually in healthcare spending.
  • Sensifai's AI platform predicts acute inflammation with 90% sensitivity using wearable-powered system.
  • The U.S. health care system could save tens of billions of dollars annually if innovative care models are adopted.

Sources:

  • "BIOTech Caucus Co-Founders Hail New FDA Reform Initiatives as Way to Enable Innovation, Create Jobs" (press release, July 9, 2025)
  • About Altesa BioSciences, Inc. (website)
  • About Sensifai Health Inc. (website)
  • "Study: AI-Powered Wearable Predicts Acute Inflammation with 90% Sensitivity" (The Lancet Digital Health, date not specified)

Read more